We speculate that anti-VEGFR2 therapy can downregulate PAK4, reprogram the GBM TME, and increase immune cell infiltration, thereby enhancing the therapeutic effect of anti-PD-L1 therapy on GBM cells. Here, PAK4 is linked to glioblastoma.